These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30342088)

  • 1. 3D cell-laden polymers to release bioactive products in the eye.
    Orive G; Santos-Vizcaino E; Pedraz JL; Hernandez RM; Vela Ramirez JE; Dolatshahi-Pirouz A; Khademhosseini A; Peppas NA; Emerich DF
    Prog Retin Eye Res; 2019 Jan; 68():67-82. PubMed ID: 30342088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes.
    Orive G; Emerich D; Khademhosseini A; Matsumoto S; Hernández RM; Pedraz JL; Desai T; Calafiore R; de Vos P
    Trends Biotechnol; 2018 Apr; 36(4):445-456. PubMed ID: 29455936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye.
    Belhaj M; Annamalai B; Parsons N; Shuler A; Potts J; Rohrer B
    J Vis Exp; 2020 Mar; (157):. PubMed ID: 32281978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.
    Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encapsulated cell technology: Delivering cytokines to treat posterior ocular diseases.
    Wang J; Fan W; Liu B; Pu N; Wu H; Xue R; Li S; Song Z; Tao Y
    Pharmacol Res; 2024 May; 203():107159. PubMed ID: 38554790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular drug delivery system: a reference to natural polymers.
    Pahuja P; Arora S; Pawar P
    Expert Opin Drug Deliv; 2012 Jul; 9(7):837-61. PubMed ID: 22703523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell treatment of degenerative eye disease.
    Mead B; Berry M; Logan A; Scott RA; Leadbeater W; Scheven BA
    Stem Cell Res; 2015 May; 14(3):243-57. PubMed ID: 25752437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.
    Kang-Mieler JJ; Dosmar E; Liu W; Mieler WF
    Expert Opin Drug Deliv; 2017 May; 14(5):611-620. PubMed ID: 27551742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics.
    Pagels RF; Prud'homme RK
    J Control Release; 2015 Dec; 219():519-535. PubMed ID: 26359125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A perspective on bioactive cell microencapsulation.
    Acarregui A; Murua A; Pedraz JL; Orive G; Hernández RM
    BioDrugs; 2012 Oct; 26(5):283-301. PubMed ID: 22715813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogels in ophthalmic applications.
    Kirchhof S; Goepferich AM; Brandl FP
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):227-38. PubMed ID: 26032290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery systems for the eye.
    Kearns VR; Williams RL
    Expert Rev Med Devices; 2009 May; 6(3):277-90. PubMed ID: 19419285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the interface of drug delivery and tissue engineering.
    Ekenseair AK; Kasper FK; Mikos AG
    Adv Drug Deliv Rev; 2013 Jan; 65(1):89-92. PubMed ID: 23000743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug delivery to target the posterior segment of the eye].
    Behar-Cohen F
    Med Sci (Paris); 2004; 20(6-7):701-6. PubMed ID: 15329823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.
    Herrero-Vanrell R; Bravo-Osuna I; Andrés-Guerrero V; Vicario-de-la-Torre M; Molina-Martínez IT
    Prog Retin Eye Res; 2014 Sep; 42():27-43. PubMed ID: 24819336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review of approaches to cell therapy in ophthalmology].
    Subbot AM; Kasparova EA; Subbot AM; Kasparova EA
    Vestn Oftalmol; 2015; 131(5):74-81. PubMed ID: 26845876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mounting of Biomaterials for Use in Ophthalmic Cell Therapies.
    Harkin DG; Dunphy SE; Shadforth AMA; Dawson RA; Walshe J; Zakaria N
    Cell Transplant; 2017 Nov; 26(11):1717-1732. PubMed ID: 29338382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2016 Nov; 32(9):563-564. PubMed ID: 27754810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.